Acrivon Therapeutics, Inc. ACRV
Set alert
1.66 USD +0.05 +3.11%
As of Nov 3, 10:26 AM ET
1.61 Day range 1.67
1.27 52-week range 3.56
- YTD
- -31.12%
- 1 year
- -28.76%
- Open
- 1.61
- Prev close
- 1.61
- Mkt cap
- 70.71M
- Vol
- 41.87K
- Avg vol
- 294.81K
- EPS
- -1.88
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.61
- High
- 1.67
- Forward P/E
- -2.31
- Beta
- 0.00
- Short ratio
- 15.38
- Inst. own
- 75.98%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 13, 2024
- 50-d avg
- 7.44
- 200-d avg
- 7.65
- 1y target
- 21.11
2Y chart
Events in this range
- Nov 13, 2024Earnings: -0.59; estimate -0.56; surprise -5.36%
- Nov 14, 2024Rating: HC Wainwright & Co. · Buy → Buy
- Nov 14, 2024Rating: BMO Capital · Outperform → Outperform
Signals (93)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | Oct 30, 2026 | 4 days ago |
| SMA: Bearish | Oct 29, 2026 | 5 days ago |
| SMA: Bullish | Oct 28, 2026 | 6 days ago |
| MACD: Buy Signal | Oct 28, 2026 | 6 days ago |
| SMA: Bearish | Oct 22, 2026 | 1 week ago |
| SMA: Bullish | Oct 20, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 13, 2026 | 3 weeks ago |
| SMA: Bearish | Oct 6, 2026 | 4 weeks ago |
| MACD: Sell Signal | Oct 2, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 24, 2026 | 1 month ago |
| SMA: Bullish | Sep 21, 2026 | 1 month ago |
| SMA: Bullish | Sep 18, 2026 | 1 month ago |
| SMA: Bearish | Sep 15, 2026 | 1 month ago |
| SMA: Bearish | Sep 15, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 1, 2026 | 2 months ago |
| RSI: Overbought | Aug 17, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 7, 2026 | 2 months ago |
| SMA: Bullish | Aug 6, 2026 | 2 months ago |
| SMA: Bearish | Jul 22, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 17, 2026 | 3 months ago |
Newest 20 of 93.
Key statistics
- Market cap
- 193.98M
- Enterprise value
- 83.54M
- Trailing P/E
- 0.00
- Forward P/E
- -2.31
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 1.16
- EPS (TTM)
- -2.66
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -31.31M
- Total cash
- 180.54M
- Total debt
- 4.22M
- Return on equity
- -37.78%
- Shares outstanding
- 31.14M
- Short % of float
- 9.15%
- 50-day average
- 7.44
- 200-day average
- 7.65
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 21.11 +1171.8% upside
Now 1.66
- Target (low)
- 16.00
- Target (mean)
- 21.11
- Target (high)
- 30.00
Ratings (0m) 10 10 buy · 0 hold · 0 sell
- Strong buy5
- Buy5
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 13, 2024
Expected Aug 13, 2024. Consensus EPS estimate -0.70286.
Financials — quick view
ACRV Revenue — quarterly 0
ACRV Net income — quarterly -17.96M
ACRV EPS — quarterly -0.43
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | -0.56 | -0.59 | -0.03 | -5.36% |
| Aug 13, 2024 | Jun 1, 2024 | -0.59 | -0.52 | +0.07 | +11.86% |
| Aug 13, 2024 | Jun 1, 2024 | -0.59 | — | — | — |
| May 14, 2024 | Mar 1, 2024 | -0.89 | — | — | — |
| May 14, 2024 | Mar 1, 2024 | -0.89 | -0.73 | +0.16 | +17.98% |
| Mar 28, 2024 | Dec 1, 2023 | -0.72 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 14, 2024 | BMO Capital | main | Outperform | Outperform |
| Nov 14, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 16, 2024 | JMP Securities | reit | Market Outperform | Market Outperform |
| Sep 16, 2024 | Ladenburg Thalmann | up | Neutral | Buy |
| Sep 16, 2024 | BMO Capital | reit | Outperform | Outperform |
| Sep 16, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Acrivon Therapeutics, Inc.
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- acrivon.com
News
- Acrivon Therapeutics To Present Dose Escalation Data From Its Current Phase 1/2 Trial Of ACR-2316 At 38th EORTC-NCI-AACR Symposium On Molecular Targets And Cancer Therapeutics
- Acrivon Announces Late-Breaking Oral Plenary Presentation of Early Phase 1/2 Clinical Results in AP3-Predicted Tumors for its First-in-Class WEE1/PKMYT1 Inhibitor ACR-2316 at the 38th EORTC-NCI-AACR Symposium
- Acrivon Therapeutics Advances ACR-7280, Showing Complete Tumor Regression In AML Models, With IND Filing Targeted For H1 2027
- Acrivon Advances ACR-7280, an Optimized, AP3-Enabled, Potential First-in-Class, Oral CDK11 Inhibitor Toward IND Filing in First Half of 2027
- 12 Health Care Stocks Moving In Wednesday's After-Market Session
- What Makes Acrivon Therapeutics, Inc. (ACRV) a New Buy Stock
- Acrivon Therapeutics, Inc. (ACRV) Just Flashed Golden Cross Signal: Do You Buy?
- Acrivon Therapeutics to Present at the 2026 Cantor Global Healthcare Conference
- Acrivon Therapeutics Appoints Michaela Levin, Ph.D., as Chief Business Officer
- Here's Why Acrivon Therapeutics, Inc. (ACRV) is a Great Momentum Stock to Buy
Your note
Sign in to keep a note on ACRV — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BLUME-JENSEN PETER | Chief Executive Officer | Stock Award(Grant) | Aug 20, 2023 | 3,218,400 |
| CHIONE, LTD. | Beneficial Owner of more than 10% of a Class of Security | Sale | Jun 25, 2023 | 0 |
| DEVROE ERIC | Chief Operating Officer | Conversion of Exercise of derivative security | May 16, 2024 | 69,097 |
| HOLM-JORGENSEN RASMUS | Chief Financial Officer | Conversion of Exercise of derivative security | Jun 15, 2023 | 29,530 |
| MILLER MARY | Officer | Stock Award(Grant) | Sep 25, 2023 | 44,287 |
| PERCEPTIVE ADVISORS, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Apr 10, 2024 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| RA Capital Management, L.P. | 26.79% | 8,340,508 | 51.96M | Sep 29, 2024 |
| Perceptive Advisors Llc | 17.22% | 5,360,858 | 33.40M | Sep 29, 2024 |
| Citadel Advisors Llc | 6.88% | 2,140,628 | 13.34M | Sep 29, 2024 |
| Sands Capital Ventures, LLC | 6.82% | 2,122,605 | 13.22M | Sep 29, 2024 |
| Wellington Management Group, LLP | 2.85% | 888,130 | 5.53M | Sep 29, 2024 |
| Marshall Wace LLP | 2.60% | 809,859 | 5.05M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.24% | 387,407 | 2.41M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 0.91% | 281,951 | 1.76M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.53% | 164,214 | 1.02M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.38% | 119,298 | 743.23K | Aug 30, 2024 |
| iShares Russell 2000 Value ETF | 0.37% | 115,408 | 718.99K | Oct 30, 2024 |
| Schwab Strategic Tr-Schwab U.S. Small Cap ETF | 0.29% | 89,261 | 556.10K | Aug 30, 2024 |